GLP-1 Medications Explained: What the Class Means and How It Works

"GLP-1" refers to a specific medicine class, GLP-1 receptor agonists, that work by mimicking a natural hormone involved in appetite and blood glucose regulation. This page explains what the classification actually means, how the class works as a whole, and which UK-licensed medications belong to it.

If you've seen "GLP-1" used as a catch-all term without much explanation of what it actually stands for, this page fills that gap, covering the classification itself before getting into the specific medications that fall under it.

Key things to know

• "GLP-1" stands for glucagon-like peptide-1, a natural hormone the body produces; GLP-1 medications mimic its effects.
• "Receptor agonist" means the medication activates the same receptor the natural hormone would, producing a similar effect.
• Several UK-licensed medications belong to this class, including Wegovy, Ozempic, Saxenda and Rybelsus, each with a different active ingredient or licensed use.
• Not all medications in this general category are identical; active ingredient, dosing schedule and licensed indication all genuinely differ between them.
• Mounjaro works on a related but distinct mechanism, since it acts on two receptor types rather than GLP-1 alone.
• Understanding the classification helps explain why different medications with overlapping mechanisms can still differ meaningfully in practice.

What Does "GLP-1" Actually Mean?

GLP-1 stands for glucagon-like peptide-1, a hormone the body naturally releases after eating. It helps regulate appetite and blood glucose levels, increases insulin release when blood sugar is high, and slows stomach emptying. GLP-1 receptor agonists activate the same receptor as this natural hormone, helping reproduce some of its effects. The duration and strength of these effects vary between medicines

How the GLP-1 Medicine Class Works for Weight Loss

Medications in this class work by mimicking the natural hormone's effects: reducing appetite, increasing feelings of fullness, slowing how quickly the stomach empties, and helping the body release more insulin when needed for blood sugar control, with best results when used alongside a healthy diet and regular exercise. This combination can support weight loss by making it easier to eat less without the same degree of hunger that would typically accompany a comparable reduction in food intake achieved through a reduced calorie diet. The same general mechanism also helps some adults lose weight, which is why medications in this class are licensed for type 2 diabetes, weight management, or both, depending on the specific medication and its approved use, with progress often tracked as a percentage of initial body weight.

UK-Licensed GLP-1 Medications

Several medicines in the UK belong to the GLP-1 receptor agonist class, but they differ in their active ingredients, formulations and approved uses. Wegovy and Ozempic contain semaglutide, while Rybelsus also contains semaglutide in tablet form. Wegovy is licensed for weight management and is available as both a weekly injection and an oral tablet in the UK. Rybelsus is licensed for type 2 diabetes, while Ozempic is also used to treat type 2 diabetes. Saxenda contains liraglutide and is licensed for weight management as a daily injection. Although these medicines share a related mechanism, they have different dosing instructions and should only be used for their approved indications under appropriate medical supervision.

Not All GLP-1 Medicines Are the Same

It's a genuine mistake to treat every medication in this general category as interchangeable. The specific active ingredient differs (semaglutide and liraglutide are the two most established examples), as does dosing frequency (some are weekly, others daily), formulation (injection versus tablet), and licensed indication (weight management, type 2 diabetes, or both, depending on the specific medication and brand). Mounjaro is a related but genuinely distinct case: it acts on two receptor types, GLP-1 and GIP, rather than GLP-1 alone, which is a meaningfully different mechanism even though it's often discussed alongside GLP-1 medications generally. Some people may need a lower dose, while others are titrated up depending on response and tolerability; the maximum dose and maximum maintenance dose also vary by medication and should always follow prescribing guidance.

This matters practically, not just as a technical distinction. Two medications sharing the "GLP-1" label can differ in how often you'd need to take them, whether by injection or tablet, and which specific health condition they're actually licensed to treat, all of which genuinely affect which option, if any, is appropriate for you individually.

Why This Classification Matters

Understanding the classification helps explain why medications with different brand names can share an overlapping general mechanism, while still genuinely differing in important, practical ways. This is part of why the specific medication a prescriber recommends matters, based on your individual health, medical history, medical conditions, other medications, treatment goals, and overall treatment plan, rather than the general class name alone determining what's appropriate for you. For example, some options act only on GLP-1, while Mounjaro also targets glucose-dependent insulinotropic polypeptide (GIP), which can affect prescribing decisions and may be considered to treat obesity or support diabetes care depending on the individual case. A qualified healthcare provider can assess suitability, and healthcare professionals can guide monitoring and next steps as part of the wider health care process if anything changes during treatment.

Starting Treatment in the UK

The online consultation process

Starting a GLP-1 medicine privately in the UK requires an assessment by a qualified prescriber before a prescription can be issued. Depending on the service, this may begin with an online questionnaire covering your medical history, current medicines, weight and relevant health conditions. The prescriber must review the information, assess whether treatment is appropriate and arrange any further checks needed. Completing a questionnaire does not guarantee a prescription; the decision depends on your individual circumstances and the medicine's licensed indications.

Pricing

The cost of private treatment varies by medicine, dose and provider. Check the provider's current pricing information for the latest costs, and confirm whether the quoted price includes the consultation, medicine, delivery and any follow-up care.

Safety Considerations

GLP-1 medications should only be used under the supervision of an appropriately qualified prescriber, following an individual clinical assessment. This page deliberately avoids specific dietary or weight-loss-rate targets, since responsible personalisation depends on that individual assessment, safe use also includes monitoring for the most common side effects and other adverse effects, and treatment decisions should rely on approved product evidence, clinical trials, and scientific evidence rather than unsupported claims. Always read the patient information leaflet for the latest safety details and instructions.

Medical Disclaimer

This content is provided for general information purposes only and does not constitute medical advice. It is not a substitute for a consultation with qualified healthcare professionals. Treatment suitability depends on an individual clinical assessment carried out by a UK-registered prescriber. Results vary between individuals. If you have concerns about your weight, general health, or mental health, speak to a pharmacist or prescriber.